FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
 
Skip Navigation LinksHome / Articles / Read Article

Print

Trinity Capital Provides $45MM Growth Capital to Neurolens

Date: Dec 06, 2023 @ 07:10 AM
Filed Under: Consumer Products

Trinity Capital announced the commitment of $45 million in growth capital to Neurolens, a company commercializing innovative solutions to optimize vision.

Neurolens offers the only prescription lenses that use a contoured prism to treat headaches, neck and shoulder pain, and eyestrain caused by eye misalignment. The company recently announced the launch of the N3, a fast and accurate way for eyecare providers to measure eye misalignment down to a fraction of a prism diopter. The company is committed to enhancing patient outcomes and assisting eye care providers in delivering much-needed relief to their patients.

"With the introduction of the N3, Neurolens will enable even more eye care professionals to access contoured prism technology in their optometry practices," said Igor DaCruz, Managing Director, Life Sciences at Trinity. "We are thrilled to work with them as they continue changing the lives of patients."

This capital will fuel continued growth in the company's operations and is expected to further accelerate the adoption of Neurolens N3 devices in optometry practices across the United States and Canada.

"While we continue to experience double-digit growth each year, the unmet patient need remains immense," said Davis Corley, Executive Chairman of Neurolens. "We are committed to leveraging innovative technology like the N3 to remove barriers to adoption and ensure that every eye care professional can access these life-changing outcomes for their patients. We are grateful that Trinity Capital Inc.—along with our dedicated investors—are embracing our mission to transform eye care."




Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.